Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Logothetis

Showing results (271-280 of 383) with videos related to

Pageof 39
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 16, 2002
The association of p21((WAF-1/CIP1)) with progression to androgen-independent prostate cancerKarim Fizazi, Luis A Martinez, Charles R Sikes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 19, 2008
Soluble ErbB3 levels in bone marrow and plasma of men with prostate cancerSue-Hwa Lin, Yu-Chen Lee, Michel B Choueiri, et al.
British Journal of Cancer|June 27, 2002
Alternating dose-dense chemotherapy in patients with high volume disseminated non-seminomatous germ cell tumoursK Fizazi, D M Prow, K-A Do, et al.
Cancer|August 27, 2014
Randomized phase 2 study of bone-targeted therapy containing strontium-89 in advanced castrate-sensitive prostate cancerMehmet Asim Bilen, Marcella M Johnson, Paul Mathew, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 6, 2011
A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinomaA J Zurita, E Jonasch, X Wang, et al.
Cancer Research Communications|November 6, 2023
Monitoring Glucocorticoid Receptor in Plasma-derived Extracellular Vesicles as a Marker of Resistance to Androgen Receptor Signaling Inhibition in Prostate CancerEmanuela Gentile, Andrew W Hahn, Jian H Song, et al.
Cancer Chemotherapy and Pharmacology|July 22, 2017
Clinical predictors of survival in patients with castration-resistant prostate cancer receiving sipuleucel-T cellular immunotherapyMehmet Asim Bilen, Kenneth R Hess, Sumit K Subudhi, et al.
Cancer Research|May 21, 2010
Cadherin-11 increases migration and invasion of prostate cancer cells and enhances their interaction with osteoblastsChih-Fen Huang, Cristina Lira, Khoi Chu, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 9, 2011
Sunitinib in combination with docetaxel and prednisone in chemotherapy-naive patients with metastatic, castration-resistant prostate cancer: a phase 1/2 clinical trialA J Zurita, D J George, N D Shore, et al.
Molecular Cancer Research : MCR|September 16, 2022
Subtype and Site Specific-Induced Metabolic Vulnerabilities in Prostate CancerFederica Mossa, Daniele Robesti, Ramachandran Sumankalai, et al.
Pageof 39

Showing results (271-280 of 383) with videos related to

Sort By:
Pageof 39
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 16, 2002
The association of p21((WAF-1/CIP1)) with progression to androgen-independent prostate cancerKarim Fizazi, Luis A Martinez, Charles R Sikes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 19, 2008
Soluble ErbB3 levels in bone marrow and plasma of men with prostate cancerSue-Hwa Lin, Yu-Chen Lee, Michel B Choueiri, et al.
British Journal of Cancer|June 27, 2002
Alternating dose-dense chemotherapy in patients with high volume disseminated non-seminomatous germ cell tumoursK Fizazi, D M Prow, K-A Do, et al.
Cancer|August 27, 2014
Randomized phase 2 study of bone-targeted therapy containing strontium-89 in advanced castrate-sensitive prostate cancerMehmet Asim Bilen, Marcella M Johnson, Paul Mathew, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 6, 2011
A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinomaA J Zurita, E Jonasch, X Wang, et al.
Cancer Research Communications|November 6, 2023
Monitoring Glucocorticoid Receptor in Plasma-derived Extracellular Vesicles as a Marker of Resistance to Androgen Receptor Signaling Inhibition in Prostate CancerEmanuela Gentile, Andrew W Hahn, Jian H Song, et al.
Cancer Chemotherapy and Pharmacology|July 22, 2017
Clinical predictors of survival in patients with castration-resistant prostate cancer receiving sipuleucel-T cellular immunotherapyMehmet Asim Bilen, Kenneth R Hess, Sumit K Subudhi, et al.
Cancer Research|May 21, 2010
Cadherin-11 increases migration and invasion of prostate cancer cells and enhances their interaction with osteoblastsChih-Fen Huang, Cristina Lira, Khoi Chu, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 9, 2011
Sunitinib in combination with docetaxel and prednisone in chemotherapy-naive patients with metastatic, castration-resistant prostate cancer: a phase 1/2 clinical trialA J Zurita, D J George, N D Shore, et al.
Molecular Cancer Research : MCR|September 16, 2022
Subtype and Site Specific-Induced Metabolic Vulnerabilities in Prostate CancerFederica Mossa, Daniele Robesti, Ramachandran Sumankalai, et al.
Pageof 39